Correction: A novel diphenylthiosemicarbazide is a potential insulin secretagogue for anti-diabetic agen (PLoS ONE (2016) 11:10 (e0164785) DOI: 10.1371/journal.pone.0164785);A novel diphenylthiosemicarbazide is a potential insulin secretagogue for anti-diabetic agen

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Sugawara, Kenji ^a   Honda, Kohei ^a   Reien, Yoshie ^b   Yokoi, Norihide ^a   Seki, Chihiro ^a   Takahashi, Harumi ^a   Minami, Kohtaro ^a   Mori, Ichiro ^c   Matsumoto, Akio ^b   Nakaya, Haruaki ^b   Seino, Susumu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; DIPHENYLTHIOSEMICARBAZIDE 108; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; INSULIN; QUINOLONE DERIVATIVE; SEMICARBAZIDE DERIVATIVE; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; THIOSEMICARBAZIDE DERIVATIVE; UNCLASSIFIED DRUG; AMINO ACID; CALCIUM; DSC108; GLUCOSE BLOOD LEVEL; PROTEIN BINDING; SULFONYLUREA RECEPTOR; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; GLUCOSE INTOLERANCE; GOTO KAKIZAKI RAT; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MIN6 CELL LINE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL LINE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HALF LIFE TIME; MEMBRANE POTENTIAL; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; PATHOLOGY; RAT; SECRETION (PROCESS);

ADMINISTRATION, ORAL; AMINO ACIDS, CYCLIC; ANIMALS; BLOOD GLUCOSE; CALCIUM; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GLYBURIDE; HALF-LIFE; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; KATP CHANNELS; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; PROTEIN BINDING; RATS; SEMICARBAZIDES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS; SULFONYLUREA RECEPTORS; THIOSEMICARBAZONES;

EID: 84992189587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170430     Document Type: Erratum

References (38)

1. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013; 12:153-75. doi: 10.1517/14740338.2013.752813 PMID: 23241069
2. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol. 1989; 54:87-143. PMID: 2484976
3. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 1999; 20:101-35. doi: 10.1210/edrv.20.2.0361 PMID: 10204114
4. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000; 49:1751-60. PMID: 11078440
5. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003; 81:133-76. PMID: 12565699
6. Inagaki N, Gonoi T, Clement JPt, Namba N, Inazawa J, Gonzalez G, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995; 270:1166-70. PMID: 7502040
7. Sakura H, Bond C, Warren-Perry M, Horsley S, Kearney L, Tucker S, et al. Characterization and variation of a human inwardly-rectifying-K-channel gene (KCNJ6): a putative ATP-sensitive K-channel subunit. FEBS Lett. 1995; 367:193-7. PMID: 7796919
8. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol. 1999; 61:337-62. doi: 10.1146/annurev.physiol.61.1.337 PMID: 10099692
9. Ashcroft FM, Gribble FM. New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol Sci. 2000; 21:439-45. PMID: 11121575
10. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011; 60:1-23. doi: 10.1016/j. metabol.2010.09.010 PMID: 21134520
11. Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009; 325:607-10. doi: 10.1126/science. 1172256 PMID: 19644119
12. Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, Inoue N, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013; 6:ra94. doi: 10.1126/scisignal.2004581 PMID: 24150255
13. Takahashi H, Shibasaki T, Park JH, Hidaka S, Takahashi T, Ono A, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015; 64:1262-72. doi: 10.2337/db14-0576 PMID: 25315008
14. Renstrom E, Barg S, Thevenod F, Rorsman P. Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action. Diabetes. 2002; 51 Suppl 1:S33-6. PMID: 11815455
15. Barg S, Renstrom E, Berggren PO, Bertorello A, Bokvist K, Braun M, et al. The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like Pglycoprotein. Proc Natl Acad Sci U S A. 1999; 96:5539-44. PMID: 10318919
16. Ozanne SE, Guest PC, Hutton JC, Hales CN. Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells. Diabetologia. 1995; 38:277-82. PMID: 7758873
17. Nagashima K, Takahashi A, Ikeda H, Hamasaki A, Kuwamura N, Yamada Y, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res Clin Pract. 2004; 66 Suppl 1:S75-8. doi: 10.1016/j.diabres.2003.12.011 PMID: 15563985
18. Drwal MN, Griffith R. Combination of ligand-And structure-based methods in virtual screening. Drug Discov Today Technol. 2013; 10:e395-401. doi: 10.1016/j.ddtec.2013.02.002 PMID: 24050136
19. Iwasaki M, Minami K, Shibasaki T, Miki T, Miyazaki J, Seino S. Establishment of new clonal pancreatic beta-cell lines (MIN6-K) useful for study of incretin/cyclic adenosine monophosphate signaling. J Diabetes Investig. 2010; 1:137-42. doi: 10.1111/j.2040-1124.2010.00026.x PMID: 24843422
20. Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, et al. Distinct effects of glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes. 2005; 54:1056-63. PMID: 15793244
21. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007; 104:19333-8. doi: 10.1073/pnas.0707054104 PMID: 18040047
22. Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001; 431:119-25. PMID: 11716850
23. Ostenson CG, Khan A, Abdel-Halim SM, Guenifi A, Suzuki K, Goto Y, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia. 1993; 36:3-8. PMID: 8436249
24. Braga RC, Alves VM, Silva AC, Nascimento MN, Silva FC, Liao LM, et al. Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. Curr Top Med Chem. 2014; 14:1899-912. PMID: 25262801
25. Ewing T, Baber JC, Feher M. Novel 2D fingerprints for ligand-based virtual screening. J Chem Inf Model. 2006; 46:2423-31. doi: 10.1021/ci060155b PMID: 17125184
26. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012; 14 Suppl 1:9-13. doi: 10.1111/j.1463-1326.2011.01507.x PMID: 22118705
27. Goto Y, Kakizaki M, Masaki N. Spontaneous Diabetes Produced by Selective Breeding of Normal Wistar Rats. Proceedings of the Japan Academy. 1975; 51:80-5.
28. Tsuura Y, Ishida H, Okamoto Y, Kato S, Sakamoto K, Horie M, et al. Glucose sensitivity of ATP-sensitive K+ channels is impaired in beta-cells of the GK rat. A new genetic model of NIDDM. Diabetes. 1993; 42:1446-53. PMID: 8375584
29. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F. Novel rapid-And short-Acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994; 269:489-95. PMID: 8182516
30. Thule PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep. 2014; 14:473. doi: 10.1007/s11892-014-0473-5 PMID: 24563333
31. Mogami H, Shibata H, Nobusawa R, Ohnota H, Satou F, Miyazaki J, et al. Inhibition of ATP-sensitive K + channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol. 1994; 269:293-8. PMID: 7895769
32. Remko M. Theoretical study of molecular structure, pK(a), lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. Journal of Molecular Structure-Theochem. 2009; 897:73-82.
33. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12:413-20. PMID: 7617530
34. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000; 50:47-60. PMID: 10840192
35. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab. 2006; 32:113-20. PMID: 16735959
36. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005; 115:2047-58. doi: 10.1172/JCI25495 PMID: 16075046
37. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006; 355:467-77. doi: 10.1056/NEJMoa061759 PMID: 16885550
38. Remedi MS, Nichols CG. Hyperinsulinism and diabetes: genetic dissection of beta cell metabolismexcitation coupling in mice. Cell Metab. 2009; 10:442-53. doi: 10.1016/j.cmet.2009.10.011 PMID: 19945402